1. Virtual care for prostate cancer survivorship: protocol for an evaluation of a nurse-led algorithm-enhanced virtual clinic implemented at five cancer centres across Canada. Pham Q, Hearn J, Bender JL, Berlin A, Brown I, Bryant-Lukosius D, Feifer AH, Finelli A, Gotto G, Hamilton R, Rendon R, Cafazzo JA. BMJ Open 2021 Apr 21:11(4).
2. Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A. Can Urol Assoc J. 2020 Dec;14(12): E616-E620.
3. Virtual care models for cancer survivorship. Pham Q, Hearn J, Gao B, Brown I, Hamilton RJ, Berlin A, Cafazzo JA, Feifer A. NPJ Digit Med. 2020 Sep 2;3:113.
4. Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience. Miller MI, Feifer A, Feldman DR, Carver BS, Bosl GJ, Motzer RJ, Bajorin DF, Sheinfeld J. Urology. 2019 Feb; 124:174-178.
5. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endrosement of an American Urological Association/American Society of Radiation Oncology/Society of Urologic Oncology Guideline,
   Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ. J Clin Oncol. 2018 Sep 5: JCO1800606
6. Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalized Prostate Cancer Survivorship Care: Prot. for a Realist Case Study of the Ned App Pham Q, Cafazzo JA, Feifer A. JMIR Res Protoc. 2017 Oct 12; 6(10): e197
7. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma Lee BH, Feifer A, Feuerstein MA, Benfante NE, Kou L, Yu C, Katt
8. Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. J Clin Oncol. 2017 Mar 27
9. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Rendon RA, Kapoor A, Breau R, Leveridge M, Feifer A, Black PC, So A. Can Urol Assoc J. 2014 May; 8(5-6): E398
10. Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery. Tarin T, Feifer A, Kimm S, Chen L, Sjoberg D, Coleman J, Russo P. J Urol. 2013 Nov 21.
11. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. Potter BJ, Leong-Sit P, Fernandes SM, Feifer A, Mayer JE Jr, Triedman JK, Walsh EP, Landzberg MJ, Khairy P. Int J Cardiol. 2013 Oct 9; 168(4): 3940-3
12. Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model. Silberstein JL, Sprenkle PC, Su D, Power NE, Tarin TV, Ezell P, Sjoberg DD, Feifer A, Fleisher M, Russo P, Touijer KA. BJU Int. 2013 Aug; 112(4): 517-25.
13. Urine neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after kidney surgery. Sprenkle PC, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, Sternberg I, Fleisher M, Russo P. J Urol. 2013 Jul;190(1):159-64.
14. Direct-to-consumer Internet promotion of robotic prostatectomy exhibits varying quality of information. Mirkin JN, Lowrance WT, Feifer AH, Mulhall JP, Eastham JE, Elkin EB. Health Aff (Millwood). 2012 Apr; 31(4): 760-9.
15. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Clin Cancer Res. 2012 Mar 1;18(5):1323-33.
16. Locally advanced prostate cancer: a population-based study of treatment patterns. Lowrance WT, Elkin EB, Yee DS, Feifer A, Ehdaie B, Jacks LM, Atoria CL, Zelefsky MJ, Scher HI, Scardino PT, Eastham JA. BJU Int. 2012 May; 109(9):1309-14.
17. Androgen deprivation and thromboembolic events in men with prostate cancer. Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB. Cancer. 2012 Jul 1; 118(13):3397-40
18. Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer. Taylor JM, Feifer A, Savage CJ, Maschino AC, Bernstein M, Herr HW, Donat SM. BJU Int. 2012 Mar; 109(6): 855-9
19. Randomized controlled trial of virtual reality and hybrid simulation for robotic surgical training. Feifer A, Al-Ammari A, Kovac E, Delisle J, Carrier S, Anidjar M. BJU Int. 2011 Nov; 108(10): 1652-6
20. Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Feifer AH, Elkin EB, Lowrance WT, Denton B, Jacks L, Yee DS, Coleman JA, Laudone VP, Scardino PT, Eastham JA. Cancer. 2011 Sep 1; 117(17): 3933-42.
21. Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors–an update. Gupta A, Feifer AH, Gotto GT, Kraus D, Motzer R, Bosl GJ, Bajorin D, Feldman DR, Carver B, Sheinfeld J. Urology. 2011 Mar; 77(3): 655-9.
22. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Feifer AH, Taylor JM, Tarin TV, Herr HW. Eur Urol. 2011 Jun; 59(6): 978-84
23. Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases. Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. J Urol. 2011 Jan; 185(1):37-42.
24. Genitourinary cancer predisposition syndromes. Gallagher DJ, Feifer A, Coleman JA. Hematol Oncol Clin North Am. 2010 Oct; 24(5): 861-83.
25. Retroperitoneoscopic living donor nephrectomy: initial experience with a unique hand-assisted approach. Capolicchio JP, Feifer A, Plante MK, Tchervenkov J. Clin Transplant. 2011 May-Jun; 25(3): 352-9
26. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Feifer A, Xie X, Brophy JM, Segal R, Kassouf W. Urology. 2010 Sep; 76(3): 652-6
27. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients. Feifer AH, Steinberg J, Tanguay S, Aprikian AG, Brimo F, Kassouf W. Urology. 2010 Jun; 75(6): 1278-82
28. Obstructive uropathy associated with primary ureteral endometrioma: case report and review of the literature. Feifer A, El-Din MA, Omeroglu A, Anidjar M. Can Urol Assoc J. 2009 Jun; 3(3)
29. Hybrid augmented reality simulator: preliminary construct validation of laparoscopic smoothness in a urology residency program. Feifer A, Delisle J, Anidjar M. J Urol. 2008 Oct;180(4):1455-9
30. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Feifer A, Corcos J. Neurourol Urodyn. 2008;27(6):475-9
31. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. Feifer AH, Fleshner NE, Klotz L.J Urol. 2002 Jul;168(1):150-4
32. Laparoscopic live donor nephrectomy: the pediatric recipient in a dual-site program. Bergman S, Feifer A, Feldman LS, Bell L, Flageole H, Tchervenkov J, Anidjar M, Stanbridge D, Fried GM. Pediatr Transplant. 2007 Jun;11(4):429-32.
33. Pharmacotherapy for erectile dysfunction. Feifer A, Carrier S Expert Opin Investig Drugs. 2008 May;17(5):679-90
34. The use of synthetic sub-urethral slings in the treatment of female stress urinary incontinence Feifer A, Corcos J. . Int Urogynecol J Pelvic Floor Dysfunct. 2007 Sep;18 (9):1087-95.

Textbook of the Neurogenic Bladder. Corcos & Schick Edit. Martin Dunitz Publishers (London UK)August 2008. Chapter 17: Suprapubic Cystostomy in the Management of Neuropathic Bladder Dysfunction

Hematology/Oncology Clinics of North America. 2010 Elsevier Inc. (London UK)-Genitourinary Cancer Predisposition Syndromes. Feifer, A, Coleman, J, Gallagher,D.

Robotic & Open Radical Prostatectomy
As a urologic oncologist, Dr. Feifer has expertise in the surgical management of patients with localized and locally advanced cancer of the prostate. If surgery is a good option for you, Dr. Feifer personalizes the approach to each patient’s cancer, and offers advanced robotic surgery for prostate removal where appropriate and open surgery when is best suits the patient. This personalized approach guarantees that each patient receives the treatment that best suits them, possibly in combination with other therapeutic modalities such as hormonal therapy, radiation, or other forms of prostate cancer treatment. In the decision-making process, statistical prediction tools and a deep focus on quality of life after any form of therapy, are important guides to what choice of therapy might best suit patient’s lifestyle. This comprehensive, compassion approach is what every patient should expect to receive under Dr. feifer’s care.

Minimally Invasive Kidney Surgery
Dr. Feifer is known for specializing in minimally invasive approaches to kidney cancer. In general, most kidney cancer is found incidentally, and there has been a dramatic improvement in our ability to prevent total kidney loss while maximizing the cancer benefit of removing tumors. Dr. Feifer specializes in extended partial nephrectomy, performed in a minimally invasive laparoscopic fashion, where the tumour is removed, and kidney reconstructed. Dr. Feifer specializes in hard-to-reach tumors, which require much experience technically, as well as having a deep understanding of kidney cancer behavior.

Metastatic & Castrate Resistant Prostate Cancer
Dr. Feifer founded and currently leads the Centre for Advanced and Metastatic Prostate Cancer at Trillium Health partners. This is a unique clinic in Canada, specializing in the comprehensive management of patients with advanced in metastatic prostate cancer, whether castrate sensitive or castrate resistant. Through this clinic, patients will have access to advanced therapeutics such as novel androgen receptor antagonist, Target in therapies for bone health, as well as access to chemotherapy as needed, radiation therapy as needed, and supported by numerous ancillary health professionals including oncology nursing, oncology pharmacy, and drug navigation. A new addition is the comprehensive men’s health program which also includes cardio oncology, sexual health rehabilitation, psycho oncology, and oncology education. There is also access to clinical trials.

REZUM ( Minimally Invasive Out Patient Procedure for BPH)
Rezūm Water Vapor Therapy is a non-surgical treatment that uses the natural energy stored in water vapor, or steam, to remove excess prostate tissue that is pressing on the urethra. Dr. Feifer has one of a select few urologists in the GTA who has performed many of these procedures with great success since this technology was approved in Canada. The procedure is brief, does not require anything more than a twilight anesthetic, requires no hospital stay, and is entirely minimally invasive. Because of the initial swelling caused by the steam, the catheter is inserted which will remain for 2 to 5 days.

High Frequency Ultrasound Ablation (HiFU) for Prostate Cancer
Certain patients with a new diagnosis of locally contain prostate cancer may be a candidate for high frequency ultrasound image guided ablation of the cancer. High intensity focussed ultrasound is a prostate cancer treatment performed by Dr. Feifer that uses a highly focussed ultrasound to pinpoint, heat, and kill prostate cancer cells using MRI guidance. Unlike radiation and surgery, who is relatively non-invasive and requires no incisions, is an outpatient procedure, and works to target the cancer itself and leave the prostate around the cancer which is normal alone. The impact of this treatment is less perturbation on urinary or sexual side effects after prostate cancer therapy. This is not a treatment for everyone, and your discussion with Dr. Feifer will involve a detailed personalize assessment of whether high frequency ultrasound is appropriate for your particular cancer case.